Activin‐A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type‐II Receptor Expression
ABSTRACT Activin‐A is elevated in pulmonary arterial hypertension (PAH) patients, and reportedly suppresses BMPR‐II. This suggests one mechanism of action for PAH drug, sotatercept, an activin‐ligand trap. However, we were unable to confirm that activin‐A reduces BMPR‐II in pulmonary endothelial cel...
Saved in:
| Main Authors: | Benjamin J. Dunmore, Nobuhiro Kikuchi, Wei Li, Paul D. Upton, Nicholas W. Morrell |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1002/pul2.70095 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CLINICAL APPLICATION OF BONE MORPHOGENETIC PROTEIN ON FRACTURE HEALING PROCESS
by: Riko Febrian Kunta Adjie
Published: (2019-12-01) -
Bone morphogenetic proteins (BMPs) at the forefront of ocular diseases and therapeutics
by: Yurong Shi, et al.
Published: (2025-07-01) -
Recent Advances in the Delivery of Bone Morphogenetic Proteins for Targeting Glioma: An Updated Review
by: Bao H, et al.
Published: (2025-05-01) -
Bone Morphogenetic Protein Coating on Titanium Implant Surface: a Systematic Review
by: Haim Haimov, et al.
Published: (2017-06-01) -
The Association of Circulating Bone Morphogenetic Protein 9 and Arterial Stiffness in Hypertensive Patients
by: Sijin Zhang, et al.
Published: (2025-06-01)